Table IV.

Joint-effect analysis of prognosis-related genes for overall survival in The Cancer Genome Atlas cohort.

Group	Expression			Overall survival
	JAK2	STAT5A	STAT6	Events/total	MST (days)	Adjusted HR (95% CI)	Adjusted P-valuea
■	Low	Low		39/100	1,005	Ref.	0.004b
■■	Low	High		63/170	1,423	0.703 (0.453-1.090)	0.115
	High	Low
■■■	High	High		28/100	2,456	0.390 (0.223-0.682)	0.001b
★	Low		Low	38/91	1,005	Ref.	<0.001b
★★	Low		High	68/188	1,423	0.536 (0.345-0.834)	0.006b
	High		Low
★★★	High		High	24/91	2,456	0.285 (0.158-0.515)	<0.0001b
●		Low	Low	45/94	802	Ref.	0.001b
●●		Low	High	57/182	1,685	0.542 (0.348-0.843)	0.007b
		High	Low
●●●		High	High	28/94	2,486	0.402 (0.238-0.677)	0.001b
▲	Low	Low	Low	24/46	768	Ref.	<0.001b
▲▲	Low	Low	High	50/147	1,852	0.516 (0.308-0.863)	0.012b
	Low	High	Low
	High	Low	Low
▲▲▲	Low	High	High	44/123	1,560	0.357 (0.204-0.625)	<0.001b
	High	Low	High
	High	High	Low
▲▲▲▲	High	High	High	12/54	3,258	0.208 (0.099-0.438)	<0.0001b

^aP-values were adjusted for radical resection, tumor stage and hepatitis B infection;

^bsignificant P-values and 95% CI. JAK2, Janus kinase 2; STAT, signal transducer and activator of transcription; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval.